Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
The Latest on: Ebola Vaccine
via Google News
The Latest on: Ebola Vaccine
- Ebola: Africa-born deadly virus keeps killing thousandson December 14, 2019 at 12:04 am
In, 2014-2015, Ebola caused global alarm when the world's worst outbreak began in West Africa, killing 11,323 people and infecting an estimated 28,600 as it swept through Liberia, Guinea and Sierra ...
- ‘SEAL Team’ Season 3, Episode 9 — Kill or Cureon December 10, 2019 at 5:16 pm
Making their way deeper into the nest, they recover the weapons grade strain of ebola in addition to the vaccines. Things aren’t going so well for Davis and she ... I hope so. My take on Episode 9 ...
- Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda's Preparedness Against Ebola Outbreakon December 8, 2019 at 9:00 pm
Dec 09, 2019 (GLOBE NEWSWIRE via COMTEX) -- COPENHAGEN, Denmark, December 9, 2019 - Bavarian Nordic A/S (omx:BAVA) BVNRY, +6.85% today announced, that its partner Janssen Pharmaceutical Companies of ...
- WHO Target 2.2 Million Children in DRC Measles Vaccination Driveon December 5, 2019 at 6:50 pm
as well as other parts of the country from a disease that is easily preventable with a vaccine,” Matshidiso Moeti, regional director of the Organization, said in a statement. “While the Ebola outbreak ...
- Violence against health workers complicating measles outbreak in Ebola-ravaged Congoon December 5, 2019 at 2:59 pm
Health workers are seen through a bullet hole left in the window of an Ebola treatment centre, which was attacked in the early hours of the morning on March 9, 2019 in Butembo ... medical kit ...
- Vaccine Group Announces Creation Of Ebola Vaccine Stockpileon December 5, 2019 at 7:57 am
The vaccine alliance GAVI announced Thursday it would invest $178 million to create a global stockpile of about 500,000 Ebola vaccines, a decision that health officials say could help prevent future ...
- Measles vaccination drive launched, North Kivu targets 2.2 million childrenon December 5, 2019 at 1:07 am
This mass follow-up campaign will ultimately reach 18.9 million children across the country by the end of the year, particularly targeting those who may have been missed by routine immunization.
- Experimental therapies offer patients a greater chance of surviving Ebola virus diseaseon December 2, 2019 at 8:39 am
The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ... An announcement made on August ...
- Investigational drugs reduce risk of death from Ebola virus diseaseon December 2, 2019 at 6:20 am
NIH/National Institute of Allergy and Infectious Diseases. (2019, December 2). Investigational drugs reduce risk of death from Ebola virus disease. ScienceDaily. Retrieved December 9, 2019 from ...
- Monoclonal Antibody Therapy for Ebola Virus Diseaseon November 27, 2019 at 2:01 pm
9 This latest trial shows unequivocally the role that monoclonal ... The European Medicines Agency approved Ervebo, the Ebola vaccine developed by Merck, on the basis of its safety profile and ...
via Bing News